Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

ivery of these outstanding quarterly results, we're building our business for the future. We're investing to enhance the value of our product pipeline, building our international structure to maximise the global reach of our products and using our strong cash generation to complete value enhancing acquisitions and in-licenses.

We now expect to see Non GAAP earnings of up to $4.20 per ADS for the full year. This includes the financial effect of the Movetis acquisition and the DAYTRANA disposal. Looking ahead, we re-iterate our aspirational target of mid-teens sales growth on average between 2009 and 2015."

FINANCIAL SUMMARY Third Quarter 2010 Unaudited Results Q3 2010 Q3 2009 Non Non US GAAP Adjustments GAAP US GAAP Adjustments GAAP $M $M $M $M $M $M Revenues 874 - 874 667 - 667 Operating income 156 142 298 92 42 134 Diluted earnings per ADS $0.52 $0.64 $1.16 $0.33 $0.16 $0.49

The Non GAAP financial measures included within this release are explained on page 26, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 21 - 24.

- Product sales were up 32% to $794 million (2009: $603 million) due to growth from both Core Products Sales (up 31% to $694 million) and ADDERALL XR(R), (up 41% to $100 million). On a CER basis, which is a Non GAAP measure, Core Product Sales were up 34%. - Core Products Sales growth was driven by both existing and new products, particularly REPLAGAL(R) (up 91% to $92 million; CER: up 103%), VYVANSE(R) (up 17% to $151 million) and recently launched VPRIV(R) ($50 million) and INTUNIV(R) ($37 million). - Total revenues were up 31% (CER: up 34%) to $874 million (2009: $667 million), as a result of higher product sales and higher royalty income on authorized generic sales of ADDERALL XR compared to Q3 2009. - Non GAAP operating income increased by $164 million, or 123%, to $298 million (2009: $134 million) as the increased investments we are making in our
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... in water with ultrasound and they,ll spin around their ... yet knows exactly. But researchers at the National Institute ... it,s fast. At up to 150,000 revolutions per minute, ... object submerged in liquid ever reported. , The discovery ... that they could be used not only for moving ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Automated cell ... and maintenance of cell culture. They allow production of ... needs of researchers in drug discovery and industries and ... in mAb production, iPSC research, cryobanking, cell-based assays, and ... contamination risk. , Analysts forecast the Global Cell ...
(Date:7/22/2014)... (NASDAQ: NEOG ) announced today that revenues ... increased 19% from the previous year to $247,405,000. Fiscal ... year,s $27,190,000. Adjusted for a 3-for-2 stock split effective ... year were $0.76, compared to $0.75 a year ago. ... year established new all-time highs for the 32-year-old company. ...
(Date:7/22/2014)... PITTSBURGH , July 22, 2014 ... maker of MD-Cu 29 antimicrobial copper announces Pullman ... to the first EPA-registered antimicrobial solid touch surface, at ... than 99.9% of MRSA, E-coli and other bacteria within 2 ... hospital in protecting against bacteria and infectious diseases in ...
Breaking Biology Technology:NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 3Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 4Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3
... Mich., Sept. 10 The primary objective of ... the delivery of,biomedical advances to the marketplace. ... at Boston University on,Friday, September 7th with noted ... Presidents of both Boston,University and Fraunhofer Gesellschaft. ...
... by prominent,Board members Robert Windom, M.D. and Steven ... with inventor Dr. Budimir Drakulic -,have this day ... approved, ambulatory 12-lead ECG cardiovascular,monitor. In private ... ten,days, the trio of cardiovascular experts and Signalife,s ...
... (Amex: PTN ) today announced it has ... melanocortin agonist drug,candidate for the treatment of male ... King Pharmaceuticals Inc. (NYSE: KG ). ... development,and marketing agreement on bremelanotide, with King exercising ...
Cached Biology Technology:'Alliance for Medical Devices, Instrumentation and Diagnostics' formed between Fraunhofer Center for Manufacturing Innovation and Boston University 2Signalife's Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor 2Signalife's Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor 3Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program 2Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program 3
(Date:7/22/2014)... In contrast to their negative reputation as disease ... and evolutionary functions that help to shape the ... new report by the American Academy of Microbiology. ... influence all life forms on the planet, from ... and driving major speciation events," states Marilyn Roossinck ...
(Date:7/22/2014)... NY -- Stem cells offer much promise for treating ... stem cell survival is poor, limiting their effectiveness. New ... survival and optimize their therapeutic function after transplantation, as ... Access , a peer-reviewed journal from Mary Ann Liebert, ... BioResearch Open Access website . ...
(Date:7/22/2014)... hear that drinking milk helps make their bones strong or that ... the idea that if something is good for us, it must ... Journal of Consumer Research , when children hear about the benefits ... predicted that when food is presented to children as making them ... learning how to read or count, they would conclude the food ...
Breaking Biology News(10 mins):Report on viruses looks beyond disease 2
... academic, government and industry researchers has completed a first draft ... important first step in accelerating the pace of research on ... that face cassava farmers around the world. Cassava is ... for more than 750 million people each day. Although it ...
... 9 Genencor, a division of Danisco, has ... American Institute of Chemical Engineers (AIChE) for its ... Robert Davis, Chair of the AIChE Awards committee, ... Marketing Director, Biomass Enzymes and Accellerase® Product Manager, ...
... A chemical culprit responsible for the rapid, mysterious death ... found by collaborating scientists at Rutgers University and the ... may hold unexpected promise in cancer research. The ... in a virus that has been attacking and killing ...
Cached Biology News:Researchers complete draft genome sequence for cassava 2Researchers complete draft genome sequence for cassava 3Researchers complete draft genome sequence for cassava 4Genencor Wins The American Institute of Chemical Engineers (AIChE) Sustainable Energy Award For Accellerase(R) Cellulosic Ethanol Enzymes 2Newly discovered fat molecule: An undersea killer with an upside 2Newly discovered fat molecule: An undersea killer with an upside 3Newly discovered fat molecule: An undersea killer with an upside 4
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
... A cleaning agent for removing ... countertops, and pipettors. It ... RNase contamination from microcentrifuge tubes ... ,RNase Zap (R) ...
Mol wt: average mol wt12,360.96 Da by calculation...
... a series of media originally developed at the ... for the large scale propagation of cells from ... used for the growth and maintenance of cell ... viruses in these cell lines. One of the ...
Biology Products: